Retrospective Cohort Study Comparing Laparoscopic One Anastomosis Gastric Bypass and Single Anastomosis Sleeve Ileal for the Treatment of Patients with Morbid Obesity and Effect on GLP-1 level: Short Term Outcomes.

Kandel, Mohamed Mosaad; El-Sayes, Islam; Ali, Reda F.; Elkeleny, Mostafa Refaie; Wael, Mohamed

doi:10.21608/asjs.2025.381620.1199

	Retrospective Cohort Study Comparing Laparoscopic One Anastomosis Gastric Bypass and Single Anastomosis Sleeve Ileal for the Treatment of Patients with Morbid Obesity and Effect on GLP-1 level: Short Term Outcomes.
Ain Shams Journal of Surgery
Volume 18, Issue 3, July 2025, Page 199-211 PDF (516.29 K)
Document Type: Original Article
DOI: 10.21608/asjs.2025.381620.1199
View on SCiNiTO
Authors
Mohamed Mosaad Kandel^* ¹; Islam El-Sayes²; Reda F. Ali³; Mostafa Refaie Elkeleny²; Mohamed Wael ²
¹Department of General Surgery, Faculty of Medicine, Port Said University, Egypt
²Department of General Surgery, Faculty of Medicine, Alexandria University, Egypt
³Department of General Surgery, Faculty of Medicine, Kafr Elshiekh University, Egypt
Abstract
Introduction: Bariatric surgery is an effective treatment for morbid obesity, though the optimal procedure remains debated. Laparoscopic one-anastomosis gastric bypass (LOAGB) and single-anastomosis sleeve ileal (SASI) bypass differ in their metabolic effects, particularly regarding glucagon-like peptide-1 (GLP-1), a key regulator of glycemic control. Aim of work: To compare the impact of LOAGB and SASI on weight loss, glycemic improvement, GLP-1 levels, diabetes remission, comorbidity resolution, and postoperative complications. Patients and methods: This retrospective cohort study included patients with severe obesity who underwent LOAGB or SASI. Outcomes at 12 months included %EWL, %EBMIL, HbA1c reduction, GLP-1 response, comorbidity resolution, and complications. Results: Both groups achieved significant weight loss with no difference in %EWL (80.9% vs. 81.2%, p = 0.738) or %EBMIL (93.7% vs. 92.8%, p = 0.285). GLP-1 levels (pmol/L) at 6 months were significantly higher in SASI (11.63 vs. 10.48 pmol/L, p = 0.01). HbA1c decreased in both groups (LOAGB: 10.46% to 5.90%; SASI: 9.89% to 5.12%, p = 0.461). GLP-1 positively correlated with weight loss (r = 0.74) and inversely with HbA1c (r = -0.79), more pronounced in SASI. Diabetes remission was higher in SASI (100% vs. 87.5%), as was hypertension resolution (100% vs. 88.9%). Complication rates, operative time, and hospital stay were similar. Conclusion: LOAGB and SASI both provide effective weight loss and metabolic improvements. SASI yields higher GLP-1 levels and superior diabetes remission, suggesting enhanced metabolic benefits. Further studies are needed to confirm long-term outcomes.
Keywords
Glycemic control; one-anastomosis gastric bypass; single anastomosis sleeve ileal bypass; weight loss; glucagon-like peptide-1


Statistics Article View: 94 PDF Download: 47